TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12954579

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 10681340

Group type: EXPERIMENTAL
Intervention: Lexipafant
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 9192194

Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mixed load (glucose+cream)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lipids load (cream)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fat oxidation
Number of subjects: 10
Study: 8447307

Group type: EXPERIMENTAL
Intervention: Closed-drainage system
Number of subjects: 79

Group type: COMPARATOR
Intervention: Open-drainage system
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic therapy
Number of subjects: 79
Study: 2937742

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 101

Group type: COMPARATOR
Intervention: Coronary bypass surgery
Number of subjects: 101
Study: 30073585

Group type: EXPERIMENTAL
Intervention: Evolocumab plus standard of care (SOC)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Evolocumab plus SOC
Number of subjects: 382
Study: 28086005

Group type: EXPERIMENTAL
Intervention: Supportive-expressive therapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 24859124

Group type: EXPERIMENTAL
Intervention: Asthma management education program (n=23), conducted a maximum of 3 times every 24 hours during hospitalization
Number of subjects: 43

Group type: COMPARATOR
Intervention: Regular treatment (Control group, n=20)
Number of subjects: 43
Study: 22399764

Group type: EXPERIMENTAL
Intervention: Efficient visual search
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inefficient visual search
Number of subjects: 0
Study: 20035529

Group type: EXPERIMENTAL
Intervention: Open minimally invasive parathyroidectomy
Number of subjects: 143

Group type: COMPARATOR
Intervention: Video-assisted parathyroidectomy (MIVAP or VAPLA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 143
Study: 19082228

Group type: EXPERIMENTAL
Intervention: 2% tea lotion
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% zinc sulphate solution
Number of subjects: 40
Study: 15930209

Group type: EXPERIMENTAL
Intervention: Morphine (loading dose of 100 microg/kg, followed by infusions of 10-30 microg/kg per hour)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (5% dextrose infusions)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12931804

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock-wave therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 10761958

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 5878

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 5878
Study: 8967584

Group type: EXPERIMENTAL
Intervention: Propofol infusion (18 mg/kg.h) with fentanyl (0.15 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propofol infusion (18 mg/kg.h) without fentanyl
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol infusion (18 mg/kg.h)
Number of subjects: 48
Study: 1346599

Group type: EXPERIMENTAL
Intervention: Thioridazine tablet (5 mg), taken 1 hour after dinner from the 8th to the 18th day of the menstrual cycle.
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 452
Study: 6206318

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 to 1.0 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Meproscillarin (0.5 to 2.0 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 29482051

Group type: EXPERIMENTAL
Intervention: Single-session, tailored, indirect brief intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Time control condition
Number of subjects: 500
Study: 26414681

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 40
Study: 25087835

Group type: EXPERIMENTAL
Intervention: 3-h Dyspnea Score (DS)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 3-h %FEV1
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Baseline DS, 3-h DS, change in DS, oxygen use at hour 3
Number of subjects: 142
Study: 23318610

Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-tourniquet
Number of subjects: 72
Study: 20833939

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18237682

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 105
Study: 15939519

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 25
Study: 12658772

Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan capsule (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: irbesartan tablet (reference)
Number of subjects: 18
Study: 10619013

Group type: EXPERIMENTAL
Intervention: Combined continuing medical education intervention (three interactive case audio-conferences plus chart reminders)
Number of subjects: 222
Study: 7851583

Group type: EXPERIMENTAL
Intervention: Women with unexplained infertility
Number of subjects: 87

Group type: COMPARATOR
Intervention: Parous controls
Number of subjects: 87
Study: 1673089

Group type: EXPERIMENTAL
Intervention: CQA 206‐291 (mixed D1‐D2 receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7036712

Group type: EXPERIMENTAL
Intervention: 1,200 mg cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1,000 mg cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitalization (one week)
Number of subjects: 0
Study: 31866083

Group type: EXPERIMENTAL
Intervention: Current HRT users
Number of subjects: 75587

Group type: COMPARATOR
Intervention: Never users of HRT
Number of subjects: 75587

Group type: EXPERIMENTAL
Intervention: HRT or oral contraception use
Number of subjects: 75587
Study: 31530055

Group type: EXPERIMENTAL
Intervention: Ultrafiltration group (dry weight gradually reduced by increasing ultrafiltration volume)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (conventional dialysis with routine ultrafiltration maintained)
Number of subjects: 64
Study: 27059218

Group type: EXPERIMENTAL
Intervention: Preheating of SLIPA at 42 °C
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group at 24 °C
Number of subjects: 80
Study: 24697256

Group type: EXPERIMENTAL
Intervention: Adaptive WM training (n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nonadaptive low-level training (active control group, n = 14)
Number of subjects: 28
Study: 24412468

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5mg/d
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0mg/d
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Cariprazine 4.5mg/d
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Risperidone 4.0mg/d
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: All active treatments
Number of subjects: 732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study: 22858806

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Basiliximab (Tac/Bas)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Tacrolimus/Mycophenolate Mofetil (Tac/MMF)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Triple therapy (Tacrolimus/Mycophenolate Mofetil/steroids)
Number of subjects: 421
Study: 19203563

Group type: EXPERIMENTAL
Intervention: Enoximone (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone (Group B)
Number of subjects: 40
Study: 17577466

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 70 mg
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 15172263

Group type: EXPERIMENTAL
Intervention: Beating heart revascularization
Number of subjects: 70

Group type: COMPARATOR
Intervention: Arrested heart revascularization
Number of subjects: 70
Study: 11350323

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.63 microg x kg(‐1))
Number of subjects: 49

Group type: COMPARATOR
Intervention: Propofol (ED50: 3.45 mg x kg(‐1) x h(‐1), ED95: 6.68 mg x kg(‐1) x h(‐1))
Number of subjects: 49
Study: 10770009

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nonbonded amalgam restorations (amalgapins or threaded pins)
Number of subjects: 38
Study: 9346217

Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide/doxorubicin/cisplatin)
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Paclitaxel (Taxol) in combination with carboplatin
Number of subjects: 1447
Study: 8462317

Group type: EXPERIMENTAL
Intervention: Gestodene (75 micrograms)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desogestrel (150 micrograms)
Number of subjects: 40
Study: 4025290

Group type: EXPERIMENTAL
Intervention: Activity counter (LSI Moving Activity Monitor)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electronic accelerometer (Caltrac Personal Activity Computer)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-reports of time spent in physical activity
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Activity counter and electronic accelerometer
Number of subjects: 80
Study: 31314569

Group type: EXPERIMENTAL
Intervention: Infants receiving ≤4 fl oz daily of formula in the first month
Number of subjects: 199

Group type: COMPARATOR
Intervention: Infants who breastfed exclusively
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Infants receiving formula daily (not specified volume)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Infants receiving ≤4 fl oz daily of formula
Number of subjects: 199
Study: 30145817

Group type: EXPERIMENTAL
Intervention: Baseline proGRP levels
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Primary endpoint (death from any cause or first hospitalization for worsening of HF)
Number of subjects: 1541

Group type: EXPERIMENTAL
Intervention: Changes in proGRP during 6 month follow-up
Number of subjects: 1541
Study: 26265372

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 987
Study: 24399164

Group type: EXPERIMENTAL
Intervention: Speed of processing training (approximately 10 hours of computerized training)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Speed of processing training
Number of subjects: 46
Study: 23377511

Group type: EXPERIMENTAL
Intervention: Clindamycin 1.2%‐tretinoin 0.025% (CLIN/RA) gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzoyl peroxide 2.5%‐adapalene 0.1% (BPO/ADA) gel
Number of subjects: 0
Study: 20207272

Group type: EXPERIMENTAL
Intervention: Patient-tailored interventions targeting specific problems and beliefs regarding the regimen
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Healthcare provider interventions emphasizing benefits of compliance
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Group interventions including tips from patients
Number of subjects: 15
Study: 19020122

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dexamethasone (Group D1)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dexamethasone (Group D2)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 166
Study: 15741051

Group type: EXPERIMENTAL
Intervention: Fish oil group (n=43)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both groups (males)
Number of subjects: 166
Study: 12614528

Group type: EXPERIMENTAL
Intervention: Reiki master
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reiki practitioner
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (historic control)
Number of subjects: 50
Study: 10403616

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Felodipine (10 mg once daily)
Number of subjects: 25
Study: 7720941

Group type: COMPARATOR
Intervention: GnRH agonist (3.75 mg IM leuprolide acetate every 28 days for 6 months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Oral contraceptive (combination monophasic for 6 months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination GnRH agonist and oral contraceptive (LA + OC for 6 months)
Number of subjects: 33
Study: 2039640

Group type: EXPERIMENTAL
Intervention: Propofol and alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopental sodium, N2O, fentanyl, isoflurane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 40
Study: 31999341

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided treat-to-target strategy
Number of subjects: 230

Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 230
Study: 30796919

Group type: EXPERIMENTAL
Intervention: Specialized Physical Therapy (SPT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular Physical Therapy (RPT)
Number of subjects: 96
Study: 27631821

Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT) (6 months or less)
Number of subjects: 1661

Group type: COMPARATOR
Intervention: Prolonged dual antiplatelet therapy (DAPT) (12 months or more)
Number of subjects: 1661
Study: 26445777

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 3.1% sodium chloride solution (hypertonic saline)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 35
Study: 23706155

Group type: EXPERIMENTAL
Intervention: Immediate feedback on alcohol consumption and access to an online intervention (Down Your Drink)
Number of subjects: 1472

Group type: COMPARATOR
Intervention: Delayed feedback and access to Down Your Drink after completion of follow‐up data at three months
Number of subjects: 1472
Study: 21537493

Group type: COMPARATOR
Intervention: p-synephrine (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: p-synephrine (50 mg) + naringin (600 mg) + hesperidin (1000 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 10
Study: 19616143

Group type: EXPERIMENTAL
Intervention: 12-week individualized home-based exercise intervention (n=46)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No-treatment control group (n=42)
Number of subjects: 88
Study: 17162192

Group type: EXPERIMENTAL
Intervention: Allopurinol (40 mg/kg/day, 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 60
Study: 15167086

Group type: EXPERIMENTAL
Intervention: Parent-infant home-visiting services (0 to 18 months of weekly visits)
Number of subjects: 63
Study: 11388520

Group type: EXPERIMENTAL
Intervention: Silicone-tipped tube with new bevel design
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wire-reinforced polyvinyl chloride tube with standard bevel
Number of subjects: 30
Study: 9671343

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-60 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 133

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 133
Study: 8071511

Group type: EXPERIMENTAL
Intervention: Supplemental nasal oxygen (2 l/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 100

Group type: COMPARATOR
Intervention: Room air (elective procedures)
Number of subjects: 100
Study: 2647817

Group type: EXPERIMENTAL
Intervention: APSAC (30 U over 5 min)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin (5,000 IU in a bolus injection)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: APSAC (anterior infarction subgroup)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: APSAC (inferior infarction subgroup)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 231
Study: 4426706

Group type: EXPERIMENTAL
Intervention: C14‐S5 strain with varying doses
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C14‐S5 strain (10^9 organisms)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 32
Study: 31718249

Group type: EXPERIMENTAL
Intervention: Inhibitory control
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cognitive theory of mind
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Emotional theory of mind
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Psychological tasks requiring high inhibitory control
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Psychological tasks not requiring high inhibitory control
Number of subjects: 112
Study: 31339677

Group type: EXPERIMENTAL
Intervention: TAF-based group (DTG + FTC + TAF)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: TDF-based group (DTG + FTC + TDF)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Standard-care group (TDF-FTC-efavirenz)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: TAF-based group
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: TDF-based group
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Standard-care group
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: DTG-containing regimens
Number of subjects: 1053
Study: 28182218

Group type: COMPARATOR
Intervention: Motivational intervention
Number of subjects: 560

Group type: COMPARATOR
Intervention: Reduction intervention
Number of subjects: 560
Study: 26061762

Group type: EXPERIMENTAL
Intervention: 10% maltodextrin solution (CHO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noncaloric placebo (PLA)
Number of subjects: 11
Study: 23863810

Group type: EXPERIMENTAL
Intervention: pioglitazone (PGZ; 45 mg/day)
Number of subjects: 441

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Higher final glucose tolerance status (NGT > IGT > T2DM)
Number of subjects: 441
Study: 21688068

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19519298

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib or Erlotinib in combination with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression free survival
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall survival and quality of life
Number of subjects: 0
Study: 16306168

Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 97
Study: 12700713

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 10831812

Group type: COMPARATOR
Intervention: Osteoarthritic group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Non-symptomatic group
Number of subjects: 20
Study: 9412258

Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol (5‐8 mg/kg.h)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Isoflurane in a maximum concentration of 0.6 vol.% in 70% nitrous oxide and 30% oxygen
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Propofol induction followed by short duration of general anaesthesia
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Propofol infusion regimen
Number of subjects: 239
Study: 7682167

Group type: EXPERIMENTAL
Intervention: Diclofenac dispersible
Number of subjects: 129

Group type: COMPARATOR
Intervention: Conventional enteric-coated tablet of diclofenac sodium 50 mg orally, thrice daily
Number of subjects: 129
Study: 3806153

Group type: EXPERIMENTAL
Intervention: Western medication (thiazide diuretic and propranolol if needed)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Chinese herbal preparation (mixture of 12 herbs)
Number of subjects: 45
Study: 31122860

Group type: EXPERIMENTAL
Intervention: NBP608
Number of subjects: 823

Group type: COMPARATOR
Intervention: Zostavax® (comparator)
Number of subjects: 823
Study: 27771274

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) administered 3 times a day for 2 consecutive days, each cycle lasting 1 to 3 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard treatment (oxygen, early mobilization, a program of breathing exercises and diuretics)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 25494205

Group type: EXPERIMENTAL
Intervention: GTRB (green tea extract enriched rye bread)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control rye bread
Number of subjects: 55
Study: 23570299

Group type: EXPERIMENTAL
Intervention: Peroxide bleaching gel Opalescence PF 20, treated 25 times for eight hours per day.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control groups stored in distilled water for two months before testing.
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control groups for ADP and IBO.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Peroxide bleaching gel Opalescence PF 20.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Electron microscopy analysis.
Number of subjects: 4